The accumulation of Tregs in the glioma microenvironment may have considerable prognostic implications, and because FH binds directly to ICOS, a promising therapeutic target, we propose that FH expression should be scrutinized when considering the effectiveness of immunotherapies against glioma. The gene discussed is ICOS; the disease is central nervous system cancer.